Creatine Guanidinoacetate Creatine deficiency syndromes GAMT deficiency Brain Development RNA interference Adeno-associated virus Among cerebral creatine deficiency syndromes, guanidinoacetate methyltransferase (GAMT) deficiency can present the most severe symptoms, and is characterized by neurocognitive dysfunction due to creatine deficiency and accumulation of guanidinoacetate in the brain. So far, every patient was found with negligible GAMT activity. However, GAMT deficiency is thought under-diagnosed, in particular due to unforeseen mutations allowing sufficient residual activity avoiding creatine deficiency, but enough guanidinoacetate accumulation to be toxic. With poorly known GAA-specific neuropathological mechanisms, we developed an RNAi-induced partial GAMT deficiency in organotypic rat brain cell cultures. As expected, the 85% decrease of GAMT protein was insufficient to cause creatine deficiency, but generated guanidinoacetate accumulation causing axonal hypersprouting and decrease in natural apoptosis, followed by induction of non-apoptotic cell death. Specific guanidinoacetateinduced effects were completely prevented by creatine co-treatment. We show that guanidinoacetate accumulation without creatine deficiency is sufficient to affect CNS development, and suggest that additional partial GAMT deficiencies, which may not show the classical brain creatine deficiency, may be discovered through guanidinoacetate measurement.
Introduction
Deficiency of guanidinoacetate methyltransferase (GAMT), creatine (Cr) synthesis second enzyme (gene GAMT), was the first identified cerebral creatine deficiency syndrome (Stöckler et al., 1994; Schulze et al., 1997; Braissant, 2014; Stöckler-Ipsiroglu et al., 2014) . The two other creatine deficiencies are arginine:glycine amidinotransferase (AGAT; Cr synthesis first enzyme; gene GATM) (Item et al., 2001) and Cr transporter (gene SLC6A8) (Salomons et al., 2001) deficiencies.
GAMT and AGAT deficiencies are autosomal recessive inherited metabolic diseases, while SLC6A8 deficiency is X-linked. Their hallmark is the virtual Cr absence when measured by 1 H-MRS in cortex and basal ganglia. Central nervous system (CNS) is the main tissue affected, with patients developing neurological symptoms in infancy, in particular intellectual disability/developmental delay and speech acquisition defects (Schulze, 2003) . GAMT deficiency can present a wide variety of symptoms from mild forms to very severe neurological phenotypes (Mercimek-Mahmutoglu et al., 2006) . Guanidinoacetate (GAA) accumulation upstream of the GAMT enzymatic block is thought to cause these severe phenotypes ranging from intractable epilepsies to autistic and automutilating behaviors as well as extrapyramidal syndrome (Schulze et al., 2001; Schulze, 2003) .
Unlike microcapillary endothelial cells at blood-brain barrier (BBB), surrounding astrocytes do not express SLC6A8, resulting in low Cr uptake efficiency and forcing the brain to complete its Cr needs by expressing AGAT and GAMT (Braissant et al., 2001; Béard and Braissant, 2010; Tachikawa and Hosoya, 2011; Braissant, 2012; Lowe et al., in press ). Under GAMT deficiency, cerebral Cr comes from periphery and the low BBB-crossing efficiency makes CNS Cr-deficient. Moreover, GAA accumulates in CNS (uptake from peripheral excess, endogenous AGAT activity with no functional GAMT; Braissant, 2012). Despite low BBB Cr permeability, SLC6A8 expression in microcapillary endothelial cells allows high Cr dosage treatment of GAMT-deficient patients who nevertheless often remain with severe intellectual disability/developmental Neurobiology of Disease 79 (2015) 14-27 Abbreviations: AAV, adeno-associated viruses; AGAT, arginine:glycine amidinotransferase; BBB, blood-brain barrier; CNS, central nervous system; Cr, creatine; DAPI, 4′,6-diamidino-2-phenylindole; EGFP, enhanced green fluorescent protein; GAA, guanidinoacetate; GABA A R, GABA A receptor; GAD, glutamate decarboxylase; GalC, galactocerebroside; GAMT, guanidinoacetate methyltransferase; GAP43, growthassociated protein 43; GFAP, glial fibrillary acidic protein; GFP, green fluorescent protein;
